Zealand Pharma initiates Phase II ZYNERGY trial combining petrelintide and enicepatide for obesity

Zealand Pharma has launched the Phase II ZYNERGY study to assess combined amylin and GLP-1/GIP receptor activity in obesity, advancing a potential multi-mechanism weight-management approach.
Zealand Pharma announced on 18 November 2026 that it had initiated the Phase II ZYNERGY dose-finding trial evaluating petrelintide, an amylin analogue, co-administered with enicepatide, a GLP-1/GIP receptor agonist, in people with obesity or overweight and at least one weight-related comorbidity.
The study will evaluate three combination dosing regimens over 40 weeks to investigate weight-loss potential, cardiometabolic outcomes and tolerability, representing an important clinical development milestone but not an announcement of positive efficacy results or regulatory approval.
Field | Content |
Company | Zealand Pharma |
Clinical Trial | ZYNERGY |
Announcement Date | 18 November 2026 |
Development Milestone | Phase II trial initiation |
Clinical Development Phase | Phase II |
Therapeutic Area | Obesity and metabolic disease |
Investigational Combination | Petrelintide plus enicepatide |
Medicine One | Petrelintide |
Medicine One Mechanism | Amylin analogue |
Medicine Two | Enicepatide |
Medicine Two Mechanism | GLP-1/GIP receptor agonist |
Eligible Population | People with obesity or overweight and at least one weight-related comorbidity |
Study Design | Dose-finding study evaluating three combination dosing regimens |
Treatment Duration | 40 weeks |
Key Study Objectives | Assess weight-loss potential cardiometabolic outcomes and tolerability |
Regulatory Status | Investigational combination; trial initiation does not constitute efficacy confirmation or approval |
Primary Source | https://rss.globenewswire.com/news-release/2026/11/18/3405372/0/en/zealand-pharma-announces-initiation-of-the-phase-2-zynergy-trial-of-petrelintide-co-administered-with-enicepatide-in-people-with-obesity-or-overweight.html |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Commenti